Evidence for Early Adjuvant Therapy (NATALEE): This global, multicenter, randomized controlled Phase III study aimed to evaluate the effect of ribociclib combined with an aromatase inhibitor as adjuvant therapy in patients with high-risk HR+/HER2- early breast cancer. This evidence concerns the gene ERBB2 and breast cancer.